Methotrexate Pharmacology and Resistance in Childhood Acute Lymphoblastic Leukemia

References

• Farber S, Diamond L K, Mercer R D, Sylvester R F, Wolff V A. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl glutamic acid (aminopterin). N. Engl. J. Med 1948; 238: 787–793
   PubMed Web of Science ®Google Scholar
• Zuelzer W W, Flatz G. Acute childhood leukemia: a ten-year study. Am. J. Dis. Child 1960; 100: 886–907
   PubMedGoogle Scholar
• Poplack D G. Acute lymphoblastic leukemia. Principles and Practice of Pediatric Oncology, P.A. A Pizzo, G D Poplack. Lippincott Co, Philadelphia, J.B 1993; 431–481
   Google Scholar
• Pediatric Oncology Group. Progress against childhood cancer: The Pediatric Oncology Group experience. Pediatr 1992; 89: 597–600
   PubMed Web of Science ®Google Scholar
• Balis F M, Holcenberg J S, Poplack D G. General principles of chemotherapy. Principles and Practice of Pediatric Oncology, P A Pizzo, G D Poplack. Lippincott Co, Philadelphia, J. B 1993; 9: 197–245
   Google Scholar
• Goldman I D, Matherly L H. The cellular pharmacology of methotrexate. Pharmacol. Ther 1985; 28: 77–100
   PubMed Web of Science ®Google Scholar
• Matherly L H. Mechanisms of receptor-mediated folate and antifolate membrane transport in cancer chemotherapy. Drug Transport in Antimicrobial and Anticancer Chemotherapy, H N Georgopapadakou. Marcel Dekker, Inc, New York 1995; 453–524
   Google Scholar
• Sirotnak F M. Obligate genetic expression in tumor cells of a fetal membrane property mediating “folate” transport: biological significance and implications of improved therapy of human cancer. Cancer Res 1985; 45: 3992–4000
   PubMed Web of Science ®Google Scholar
• Matherly L H, Czajkowski C A, Angeles S M. Identification of a highly glycosylated methotrexate membrane carrier in K562 erythroleukemia cells up-regulated for tetrahydrofolate cofactor and methotrexate transport. Cancer Res 1991; 51: 3420–3426
   PubMed Web of Science ®Google Scholar
• Freisheim J H, Ratnam M, McAlinden T P, Prasad K M. R, Williams F E, Westerhof G R, Schornagel J H, Jansen G. Molecular events in the membrane transport of methotrexate in human CCRF-CEM leukemia cell lines. Adv. Enzyme Regul 1992; 32: 17–31
   PubMedGoogle Scholar
• Dixon K H, Lampher B C, Chiu J, Kelley K, Cowan K H. A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport-deficient cells. J. Biol. Chem 1994; 269: 17–20
   PubMed Web of Science ®Google Scholar
• Williams F M. R, Murray R C, Underhill T M, Flintoff W F. Isolation of a hamster cDNA clone coding for a function involved in methotrexate uptake. J. Biol. Chem 1994; 269: 5810–5816
   PubMed Web of Science ®Google Scholar
• Prasad P D, Ramamoorthy S, Leibach F H, Ganapathy V. Molecular cloning of the human placental folate transporter. Biochem. Biophys. Res. Commun 1995; 206: 681–687
   PubMed Web of Science ®Google Scholar
• Williams F M. N, Flintoff W F. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. J. Biol. Chem 1995; 270: 2087–2092
   Web of Science ®Google Scholar
• Wong S C, Proefke S A, Bhushan A, Matherly L H. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport defective Chinese hamster ovary cells. J. Biol. Chem 1995; 270: 17468–17475
   PubMed Web of Science ®Google Scholar
• Matherly L H, Seither R L, Goldman I D. The basis of antifolate cytotoxicity, selectivity and metabolic transformations: effects on utilization of endogenous and exogenous folate cofactors. In Anticancer Drugs: Antimetabolite Metabolism and Natural Anticancer Agents, G Powis. Pergamon Press, Oxford, Oxford 1994; 139–177
   Google Scholar
• Allegra C J, Chabner B A, Drake J C, Lutz R, Rodbard D, Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J. Biol. Chem 1985; 260: 9720–9726
   PubMed Web of Science ®Google Scholar
• Allegra C J, Drake J, Jolivet J, Chabner B A. Inhibition of phosphoribosyl aminoimidazolecarboxamide trans-formylase by methotrexate and dihydrofolate acid polyglutamates. Proc. Natl. Acad. Sci. USA 1985; 82: 4881–4885
   PubMed Web of Science ®Google Scholar
• Allegra C J, Drake J C, Jolivet J, Chabner B A. Inhibition of folate-dependent enzymes by methotrexate polyglutamates. Proceedings of the second workshop onfolyl andantifolyl polyglutamates, IDD I Goldman. Praeger Publishers, New York 1985; 348–359
   Google Scholar
• Matherly L H, Barlowe C K, Phillips V M, Goldman I D. The effects of 4-aminoantifolates on 5-formyltetrahydrofo-late metabolism in L1210 cells. A biochemical basis for the selectivity of leucovorin rescue. J. Biol. Chem 1987; 262: 710–717
   PubMed Web of Science ®Google Scholar
• Fischer G A. Defective transport of amethopterin (methotrexate) as a mechanism of resistance to the antimetabolite in L5178Y leukemic cells. Biochem. Pharmacol 1962; 11: 1233–1237
   PubMed Web of Science ®Google Scholar
• Biedler J L, Albrecht A M, Hutchinson D J, Spengler B A. Drug response, dihydrofolate reductase, and cytogenetics of amethopterin resistant Chinese hamster cells in vitro. Cancer Res 1972; 32: 153–161
   PubMed Web of Science ®Google Scholar
• Schimke R T. Gene amplification, drug resistance, and cancer. Cancer Res 1984; 44: 1735–1742
   PubMed Web of Science ®Google Scholar
• Cowan K H, Jolivet J. A methotrexate resistant human breast cancer cell line with multiple defects, including diminished formation of methotrexate polyglutamates. J. Biol. Chem 1984; 259: 10793–10800
   PubMed Web of Science ®Google Scholar
• Frei E, Rosowsky A, Wright J E, Cucchi C A, Lippke J A, Ervin T J, Jolivet J, Haseltine W A. Development of methotrexate resistance in a human squamous cell carcinoma of the head and neck in culture. Proc. Natl. Acad. Sci. USA 1984; 81: 2873–2877
   PubMed Web of Science ®Google Scholar
• Pizzorno G, Mini E, Coronnello M, McGuire J J, Moroson B A, Cashmore A R, Dreyer R N, Lin J T, Mazzei T, Periti P, Bertino J R. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. Cancer Res 1988; 48: 2149–2155
   PubMed Web of Science ®Google Scholar
• McCloskey D, McGuire J J, Russell C A, Rowan B G, Bertino J R, Pizzorno G, Mini E. Decreased foly-polyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J. Biol. Chem 1991; 226: 6181–6187
   Google Scholar
• Goldman I D, Gupta V, White J C, Loftfield S. Exchangeable intracellular methotrexate levels in the presence and absence of vincristine at extracellular drug concentrations relevant to those achieved in high dose methotrexate-folinic acid “rescue” protocols. Cancer Res 1976; 36: 276–279
   PubMed Web of Science ®Google Scholar
• Niethammer D, Diddens H, Gekeler V, Frese G, Handgretinger R, Henze G, Schmidt H, Probst H. Resistance to methotrexate and multidrug resistance in childhood malignancies. Adv. Enzyme Reg 1989; 29: 231–235
   PubMedGoogle Scholar
• Goker E, Waltham M, Kheradpour A, Trippett T, Mazumdar M, Elisseyeff Y, Schnieders B, Steinherz P, Tan T, Berman E, Bertino J R. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood 1995; 86: 677–684
   PubMed Web of Science ®Google Scholar
• Kaufman R J, Bertino J R, Schimke R T. Quantitation of dihydrofolate reductase in individual parental and methotrexate-resistant murine cells. Use of a fluorescence activated cell sorter. J. Biol. Chem 1978; 253: 5852–5860
   PubMed Web of Science ®Google Scholar
• Assaraf Y G. Identification of methotrexate transport deficiency in mammalian cells using fluo-resceinated methotrexate and flow cytometry, R T Schimke. Proc. Natl. Acad. Sci, USA 1987; 84: 7154–7158
   Google Scholar
• Rosowsky A, Wright J E, Shapiro H, Beardsley P, Lazarus H. A new fluorescent dihydrofolate reductase probe for studies of methotrexate resistance. J. Biol. Chem 1982; 257: 14162–14167
   PubMed Web of Science ®Google Scholar
• Wright J E, Rosowsky A, Boeheim K, Cucchi C A, Frei E. Flow cytometric studies of methotrexate resistance in human squamous carcinoma cell cultures. Biochem. Pharmacol 1987; 36: 1561–1564
   PubMed Web of Science ®Google Scholar
• Trippett T, Schlemmer S, Elisseyeff Y, Goker E, Wachter M, Steinherz P, Tan C, Berman E, Wright J E, Rosowsky A, Schweitzer B, Bertino J R. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia. Blood 1992; 80: 1158–1162
   PubMed Web of Science ®Google Scholar
• Matherly L H, Taub J W, Ravindranath Y, Proefke S A, Wong S C, Gimotty P, Buck S, Wright J E, Rosowsky A. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood 1995; 85: 500–509
   PubMed Web of Science ®Google Scholar
• Whitehead V M, Vuchich M J, Bernstein M, McClain K, Fort D, Shuster J, Lauer S, Akabutu J, Bowen T, Devine S, Payment C. Differences in chain length of methotrexate polyglutamates in lymphoblasts from children with T- and B-lin-eage acute lymphoblastic leukemia (ALL). Proc. Am. Assoc. Cancer Res 1992; 33–405, (abstr)
   Google Scholar
• Goker E, Lin J T, Trippett T, Elisseyeff Y, Tong W P, Niedzwiecki D, Tan C, Steinherz P, Schweitzer B I, Bertino J R. Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia 1993; 7: 1000–1004
   PubMed Web of Science ®Google Scholar
• Barredo J C, Synold T W, Laver J, Relling M V, Pui C.-H, Priest D G, Evans W E. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 1994; 84: 564–569
   PubMed Web of Science ®Google Scholar
• Synold T W, Relling M V, Boyett J M, Rivera G K, Sandlund J T, Mahmoud H, Crist W M, Pui C H, Evans W E. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphocytic leukemia. J. Clin. Invest 1994; 94: 1996–2001
   PubMed Web of Science ®Google Scholar
• Whitehead V M, Rosenblatt D S, Vuchich M J, Beaulieu D. Methotrexate polyglutamate synthesis in lymphoblasts from children with acute lymphoblastic leukemia. Dev. Pharmacol. Ther 1984; 10: 443–448
   Google Scholar
• Whitehead V M, Rosenblatt D S, Vuchich M J, Shuster J J, Witte A, Beaulieu D. Accumulation of methorexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood 1990; 76: 44–49
   PubMed Web of Science ®Google Scholar
• Whitehead V M, Vuchich M J, Lauer S J, Mahoney D, Carroll A J, Shuster J J, Esseltine D W, Payment C, Look A T, Akabutu J, Bowen T, Taylor L D, Camitta B, Pullen D J. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (>50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 1992; 80: 1316–1323
   PubMed Web of Science ®Google Scholar
• Lenz H J, Danenberg K, Schnieders B, Goeker E, Peters G J, Garrow T, Shane B, Bertino J R, Danenberg P V. Quantitative analysis of folylpolyglutamate syntetase gene expression in tumor tissues by the polymerase chain reaction: marked variation of expression among leukemia patients. Oncol. Res 1994; 6: 329–335
   PubMed Web of Science ®Google Scholar
• Rhee M S, Wang Y, Nair M G, Galivan J. Acquisition of resistance to antifolates caused by enhanced γ-glutamyl hydrolase activity. Cancer Res 1993; 53: 2227–2230
   PubMed Web of Science ®Google Scholar
• Borsi J D, Moe P J. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia. Cancer 1987; 60: 5–13
   PubMed Web of Science ®Google Scholar
• Goldman I D, Lichtenstein N S, Oliverio V T. Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J. Biol. Chem 1968; 243: 5007–5017
   PubMed Web of Science ®Google Scholar
• Fry D W, Yalowich J C, Goldman I D. Rapid formation of poly-γ—glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in Ehrlich ascites tumor cells. J. Biol. Chem 1982; 257: 1890–1896
   PubMed Web of Science ®Google Scholar
• George S, Cichowicz D J, Shane B. Mammalian folyl-γ—glutamate synthetase. 3. Specificity for folate analogues. Biochemistry 1987; 26: 522–529
   PubMed Web of Science ®Google Scholar
• Teresi M E, Crom W R, Choi K E, Mirro J, Evans W E. Methotrexate bioavailability after oral and intramuscular administration in children. J. Pediatr 1987; 110: 788–792
   PubMed Web of Science ®Google Scholar
• Evans W E, Crom W R, Abromowitch M, Dodge R, Look T, Bowman P, George S L, Pui C H. Clinical pharam-codynamics of high-dose methotrexate in acute lymphocytic leukemia. N. Engl. J. Med 1986; 314: 471–477
   PubMed Web of Science ®Google Scholar
• Camitta B, Leventhal B, Lauer S, Shuster J J, Adair S, Casper J, Civin C, Graham M, Mahoney D, Munoz L, Kiefer G, Kamen B. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. J. Clin. Oncol 1989; 7: 1539–1544
   PubMed Web of Science ®Google Scholar
• Balis F M, Poplack D G. Central nervous system pharmacology of antileukemia drugs. Am. J. Pediat. Hematol. Oncol 1989; 11: 74–86
   PubMedGoogle Scholar
• Borsi J D, Sagen E, Romslo I, Slordal L, Moe P J. 7-Hydroxymethotrexate concentrations in serum and cerebrospinal fluid of children with acute lymphoblastic leukemia. Cancer 1990; 60: 5–13
   Web of Science ®Google Scholar
• Drake J C, Allegra C J, Baram J, Kaufman B T, Chabner B A. Effects on dihydrofolate reductase of methotrexate metabolites and intracellular folates formed during methotrexate exposure of human breast cancer cells. Biochem. Pharmacol 1987; 36: 2416–2418
   PubMed Web of Science ®Google Scholar
• Sholar P W, Baram J, Seither R, Allegra C J. Inhibition of folate-dependent enzymes by 7-OH-methotrexate. Biochem. Pharmacol 1988; 37: 3531–3534
   PubMed Web of Science ®Google Scholar
• Jacobs S A, Stoller R G, Chabner B A, Johns D G. 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J. Clin. Invest 1976; 57: 534–538
   PubMed Web of Science ®Google Scholar
• Erttmann R, Bielack S, Landbeck G. Kinetics of 7-hydroxy-methotrexate after high dose methotrexate therapy. Cancer Chemother. Pharmacol 1985; 15: 101–104
   PubMed Web of Science ®Google Scholar
• Payet B, Fabre I, Fabre G, Cano J P. Interactions between 7-hydroxy-methotrexate and folinic acid in RAJI cells. in vitro. Cancer Lett 1988; 39: 45–58
   PubMed Web of Science ®Google Scholar
• Pui C.-H, Crist W M, Look A T. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 1990; 76: 1449–1463
   PubMed Web of Science ®Google Scholar
• Raimondi S C, Roberson P, Pui C.-H, Behm F G, Rivera G K. Hyperdiploid (47–50) acute lymphoblastic leukemia in children. Blood 1992; 79: 3245–3252
   PubMed Web of Science ®Google Scholar
• Raimondi S C, Pui C.-H, Hancock M, Behm F G, Santana V M, Rivera G K. Heterogeneity of hyperdiploid (51–67) childhood acute lymphoblastic leukemia. Proc. Am. Assoc. Clin. Oncol 1995; 14: 1029a, (abstr)
   Google Scholar
• Fong C, Brodeur G M. Downs's syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis. Cancer Genet. Cytogenet 1987; 28: 55–76
   PubMed Web of Science ®Google Scholar
• Robison L. Down syndrome and leukemia. Leukemia 1992; 6(suppl 1)5–7
   PubMed Web of Science ®Google Scholar
• Trueworthy R, Shuster J, Look T, Crist W, Borowitz M, Carroll A, Frankel L, Harris M, Wagner H, Haggard M, Mosijczuk A, Pullen J, Steuber P, Land V. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. J. Clin. Oncol 1992; 10: 606–613
   PubMed Web of Science ®Google Scholar
• Harris M B, Shuster J J, Carroll A, Look A T, Borowitz J J, Crist W M, Nitschke R, Pullen J, Steuber C P, Land V J. Trisomy of leukmic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood 1992; 79: 3316–3324
   PubMed Web of Science ®Google Scholar
• Kaspers G J. L, Smets L A, Pieters R, Van Zantwijk C H, Van Wering E R, Veerman A J. P. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995; 85: 751–756
   PubMed Web of Science ®Google Scholar
• Garre M L, Relling M V, Kalwinsky D, Dodge R, Crom W R, Abromowitch M, Pui C H, Evans W E. Pharmacokinetics and toxicity of methotrexate in children with Down's syndrome and acute lymphocytic leukemia. J. Pediatr 1987; 111: 606–612
   PubMed Web of Science ®Google Scholar
• Peeters M, Poon A. Down syndrome and leukaemia: unusual clinical aspects and unexpected methotrexate sensitivity. Eur. J. Pediatr 1987; 146: 416–422
   PubMed Web of Science ®Google Scholar
• Yang-Feng T L, Ma Y Y, Liang R, Prasad P D, Leibach F H, Ganapathy V. Assignment of the human folate transporter gene to chromosome 21q22.3 by somatic cell hybrid analysis and in situ hybridization. Biochem. Biophys. Res. Commun 1995; 210: 874–879
   PubMed Web of Science ®Google Scholar